Form SC14D9C LISATA THERAPEUTICS, Filed by: LISATA THERAPEUTICS, INC.
Tweet
Share
E-mailUNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14D-9
Solicitation/Recommendation Statement
Under Section 14(d)(4) of the Securities Exchange Act of 1934
LISATA THERAPEUTICS, INC.
(Name of Subject Company)
LISATA THERAPEUTICS, INC.
(Name of Person Filing Statement)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
128058302
(CUSIP Number of Class of Securities)
David J. Mazzo, Ph.D.
Chief Executive Officer
Lisata Therapeutics, Inc
P.O. Box 173
Liberty Corner, NJ 07938
(908) 841-0100
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications
on Behalf of the Person Filing Statement)
With copies to:
Jeffrey P. Schultz, Esq.
Mintz Levin Cohn Ferris Glovsky &
Popeo, P.C.
919 Third Avenue
New York, NY 10022
(212) 935-3000
| ☒ |
Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.
|
The information set forth under Item 1.01 of the Current Report on Form 8-K filed by Lisata Therapeutics, Inc. on June 9, 2026 (including all exhibits attached thereto and incorporated therein by reference) is incorporated herein by reference.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.
- Helix Biopharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Nine-Month Periods Ended April 30, 2026
- Caprock Announces Consistent High-Grade Intercepts from the Final Three Deep Drill Holes at Destiny, Including 8.32 g/t Au over 2.6m
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
